Gain critical insights into the US biosimilar landscape to help drive your biosimilar strategy. Through a synthesis of proprietary and public data, we analyze the market for Infliximab (Remicade® and its biosimilar competitors) to discuss potential predictors of future market behavior.
Biosimilar manufacturers should be aware that they’ll need to go beyond pricing discounts and develop partnerships with friendly constituents to expand market share and ensure the continued viability of the market.
We use our own and third parties cookies to improve your experience and our services. If you continue browsing, we take that to mean that you accept their uses and information.